182 related articles for article (PubMed ID: 10993491)
1. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis.
Yeh JH; Chiu HC
J Neurol; 2000 Jul; 247(7):510-3. PubMed ID: 10993491
[TBL] [Abstract][Full Text] [Related]
2. Optimal volume of processed plasma and total number of selective plasmapheresis sessions in the treatment of patients with severe generalized myasthenia gravis.
Yeh JH; Chiu HC
J Clin Apher; 1999; 14(4):177-80. PubMed ID: 10611627
[TBL] [Abstract][Full Text] [Related]
3. Removal Characteristics of Immunoadsorption with the Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis.
Ohkubo A; Okado T; Sakurasawa T; Maeda T; Itagaki A; Yamamoto H; Miyamoto S; Seshima H; Kurashima N; Mori T; Iimori S; Sohara E; Rai T; Uchida S; Naito S
Ther Apher Dial; 2019 Jun; 23(3):271-278. PubMed ID: 31025833
[TBL] [Abstract][Full Text] [Related]
4. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
[TBL] [Abstract][Full Text] [Related]
5. [Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column].
Yeh JH; Chiu HC
J Microbiol Immunol Infect; 1999 Jun; 32(2):121-5. PubMed ID: 11565565
[TBL] [Abstract][Full Text] [Related]
6. The six year experience of plasmapheresis in patients with myasthenia gravis.
Chiu HC; Chen WH; Yeh JH
Ther Apher; 2000 Aug; 4(4):291-5. PubMed ID: 10975476
[TBL] [Abstract][Full Text] [Related]
7. [Plasmapheresis in patients with myasthenia gravis].
Konishi T
Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
[TBL] [Abstract][Full Text] [Related]
8. Predicting the course of myasthenic weakness following double filtration plasmapheresis.
Yeh JH; Chen WH; Chiu HC
Acta Neurol Scand; 2003 Sep; 108(3):174-8. PubMed ID: 12911460
[TBL] [Abstract][Full Text] [Related]
9. [Soluble adhesive molecules and cytokines in patients with myasthenia gravis treated with plasmapheresis].
Tesar V; Jelínková E; Jirsa M; Bakosová N; Pit'ha V; Chábová V
Cas Lek Cesk; 1998 Nov; 137(21):654-9. PubMed ID: 9929930
[TBL] [Abstract][Full Text] [Related]
10. Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule.
Yeh JH; Chiu HC
Acta Neurol Scand; 1999 Mar; 99(3):147-51. PubMed ID: 10100957
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: A case series of nine patients and literature review.
Bennani HN; Lagrange E; Noble J; Malvezzi P; Motte L; Chevallier E; Rostaing L; Jouve T
J Clin Apher; 2021 Jun; 36(3):348-363. PubMed ID: 33349954
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary function study of myasthenia-gravis patients treated with double-filtration plasmapheresis.
Chiu HC; Yeh JH; Chen WH
J Clin Apher; 2003; 18(3):125-8. PubMed ID: 14569603
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic apheresis in myasthenia gravis patients: a six year follow-up.
Schneidewind JM; Zettl UK; Winkler RE; Ramlow W; Tiess M; Hofmann D; Michelsen A; Weber G; Kinze EM; Adam U; Hauk L; Behnecke R; Klinkmann H
Ther Apher; 1999 Nov; 3(4):298-302. PubMed ID: 10608721
[TBL] [Abstract][Full Text] [Related]
14. Prethymectomy plasmapheresis in myasthenia gravis.
Yeh JH; Chen WH; Huang KM; Chiu HC
J Clin Apher; 2005 Dec; 20(4):217-21. PubMed ID: 16035101
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of clinical effects between plasma adsorption and double filtration plasmapheresis in patients with myasthenia gravis.
Okada H; Moriwaki K; Sugahara S; Nakamoto H; Hosokawa T; Hamaguchi K; Suzuki H
Ther Apher; 1997 Nov; 1(4):343-7. PubMed ID: 10225728
[TBL] [Abstract][Full Text] [Related]
16. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis.
Pták J
Transfus Apher Sci; 2004 Apr; 30(2):125-9. PubMed ID: 15062750
[TBL] [Abstract][Full Text] [Related]
17. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.
Köhler W; Bucka C; Klingel R
J Clin Apher; 2011 Dec; 26(6):347-55. PubMed ID: 22095647
[TBL] [Abstract][Full Text] [Related]
18. Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange.
Tesar V; Jelínková E; Jirsa M; Bakosová M; Pitha P; Chábová V
Blood Purif; 2000; 18(2):115-20. PubMed ID: 10838470
[TBL] [Abstract][Full Text] [Related]
19. The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers.
Barnett C; Katzberg H; Nabavi M; Bril V
J Clin Neuromuscul Dis; 2012 Jun; 13(4):201-5. PubMed ID: 22622164
[TBL] [Abstract][Full Text] [Related]
20. Double filtration plasmapheresis in myasthenia gravis--analysis of clinical efficacy and prognostic parameters.
Yeh JH; Chiu HC
Acta Neurol Scand; 1999 Nov; 100(5):305-9. PubMed ID: 10536917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
